Eli Lilly Makes An $8B Cancer Genetics Bet With Loxo Acquisition

January 07, 2019 | Eli Lilly is set to acquire Loxo Oncology for approximately $8 billion---a deal that brings to the Indianapolis pharmaceutical giant a class of drugs that treat cancers with particular genetic signatures. Xconomy